Sign up
Pharma Capital

Akers Biosciences enjoys stellar second quarter with sales up 25% year-on-year

Revenues were US$1.2mln for the three-month period ended June 30, up around 25% on the same period last year and 1.8-times the turnover recorded in the first-quarter.
financial-report.jpg
The numbers are starting add up for Akers

Rapid diagnostics specialist Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) said quarterly sales were the strongest since the company’s admission to America’s NASDAQ market in 2014.

Revenues were US$1.2mln for the three-month period ended June 30, up around 25% on the same period last year and 1.8-times the turnover recorded in the first-quarter.

Sales were derived from all of its main markets – the US, China and the rest of the world – and spread across its main product lines, including its breakthrough rapid heparin allergy test.

The company has developed a range of breath-test diagnostics which monitor conditions such as oxidative stress, cholesterol levels and whether the body is burning fat.



Register here to be notified of future AKR Company articles
View full AKR profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.